Bacterial DNA induces a proinflammatory immune response in patients with decompensated cirrhosis

We read with interest the study of Thalheimer et al (Gut 2005;54:556–63) in which they reviewed actual knowledge regarding the influence of infection on haemodynamics, vascualar haemorrhage, hepatic encephalopathy, liver damage, and other effects. We agree with these assumptions and would like to add information not quoted in the paper that may help explain some of the immune abnormalities usually found in patients with advanced decompensated cirrhosis. As the authors detailed in their paper, our group has reported on the detection of bacterial DNA in a significant proportion of patients with cirrhosis and culture negative non-neutrocytic ascites, and has also shown that these fragments may last in blood for variable periods of time. In our opinion, the presence of bacterial DNA is not only representative in itself of the presence of bacteria (either viable or non-viable) in our patients, but induces similar immunological changes as endotoxin or viable bacteria. The question of whether bacterial DNA also induces haemodynamic disturbances is currently under investigation.

Bacterial DNA contains a series of CpG motifs that join toll-like receptor 9 and activates a series of intracellular mechanisms leading to the synthesis of proinflammatory cytokines. We therefore observed that peritoneal white cells obtained from ascitic fluid in patients with the presence of bacterial DNA showed a marked activation pattern when the intracellular presence of cytokines involved in a type 1 immune response by means of flow cytometry was analysed, and also an increased ability to secrete this type of cytokines when cultured. Importantly, white cells in culture also displayed a significantly higher ability to secrete nitric oxide than cells obtained from patients without the presence of bacterial DNA, and nitric oxide levels showed a direct and significant relationship with the inducible form of nitric oxide synthase (iNOS), suggesting that in this setting, ascitic fluid nitric oxide synthesis is, at least in part, induced by this isoform. Nitric oxide is a key agent in the pathogenesis of haemodynamic disturbances present in patients with advanced cirrhosis, and its levels are further increased in patients with hepatoportal syndrome. Ascitic fluid nitric oxide levels are independently related to the development of renal impairment in patients with spontaneous bacterial peritonitis.

Thus the relation between the presence of bacterial DNA in blood and the ability to secrete proinflammatory cytokines and nitric oxide by cells of the immune system in patients with decompensated cirrhosis suggest that endotoxin and viable bacteria should not only be taken into account in the design of new research protocols, but also bacterial DNA, or similar molecules, as demonstration of the presence of bacteria in patients with advanced cirrhosis.

References

Author’s reply
We are grateful to Such et al for their comments on our review. As we had outlined, the influence of bacterial infection on the pathophysiology of cirrhosis is indeed an important one and Such et al have contributed significantly to this topic. We were aware of their data, but unfortunately some of it could not be retained in the final version of our paper due to editorial restrictions. Nevertheless, we agree that the presence of bacterial DNA, in the absence of viable bacteria or endotoxaemia, might be an additional step in the sequence of events outlined in fig 2 of our review, maybe even preliminary to endotoxaemia.

U Thalheimer, C K Triantos, D N Samonakis, D Patch, A K Burroughs
Liver Transplant and Hepatobiliary Medicine, Royal Free Hospital, London, UK
Correspondence to: Professor A K Burroughs, Liver Transplant and Hepatobiliary Medicine, Royal Free Hospital, Hampstead, London NW3 2QG, UK; andrew.burroughs@royalfree.nhs.uk
Conflict of interest: None declared.

Perinatal passive smoke exposure may be more important than childhood exposure in the risk of developing childhood IBD

The large case control study of patients with inflammatory bowel disease (IBD) in the French paediatric population by Baron et al has clarified the role of well established genetic and environmental risk factors, as well as suggesting novel environmental risk factors (Gut 2005;54:357–63). However, we caution the authors on dismissal of the role of passive smoking in the risk of IBD development in childhood. Our own data would suggest that analysing smoking data during pregnancy and at birth is more important in the development of childhood IBD, rather than assessing smoking during childhood and at disease onset, as performed in this current study.

We have performed a case control study in South East Scotland of children with early onset IBD, matching cases of IBD diagnosed at less than 16 years of age with same sex and age (±1 year) controls attending the same general practice. In total, we matched 62 pairs of cases and controls, with a median age of disease onset in cases of 10.6 years. We demonstrated that parental smoking during pregnancy and around the time of birth was more common in parents of IBD cases, at 54% compared with control parents at 29% (p = 0.01; odds ratio (OR) 2.87 (95% confidence interval (CI) 1.23–6.66)). Maternal smoking during pregnancy and at birth was also more common in IBD cases than in controls, at 23% versus 6.2% (p = 0.04; OR 4.46 (95% CI 1.16–17.1)), and in mothers of patients with Crohn’s disease, at 27.8% versus control mothers at 8.3% (p = 0.03; OR 4.23 (95% CI 1.05–16.97)). There was no significant effect seen when paternal smoking in pregnancy and at birth was analysed in IBD cases versus controls (p = 0.27). These
data replicate the publication by Lashner and colleagues who studied 72 IBD cases and controls and found a similar relationship to smoking at birth—this was increased in children who later developed IBD in childhood (OR 3.02) and CD in childhood (OR 5.32). The authors of this study also demonstrated that maternal smoking at birth was important in the development of IBD and CD.

We agree with the findings of Baron et al. that parental/passive smoke exposure outside of the perinatal period, including at the time of IBD diagnosis, is not associated with the risk of developing IB in children (p = 0.18). This lack of association between passive smoke exposure in childhood and development of childhood IBD has also been replicated by Lashner and colleagues. It is important to note that the other studies quoted by Baron et al. in relation to the risk of passive smoking in IBD patients relate to the risk of adult onset IBD after passive smoke exposure during childhood, not the risk of developing IBD as a child. The mechanism by which smoke exposure during pregnancy and at birth leads to an increased risk of childhood IBD can only be a subject for speculation, but it is interesting to note a recent study that has demonstrated chromosomal abnormalities in fetal epithelial cells in women who smoke during pregnancy.

In conclusion, our study agrees with previously published data to suggest a role between passive smoke exposure during pregnancy and at birth with the risk of childhood development of IBD. When assessing passive smoking in relation to childhood onset IBD, investigators should survey smoke exposure in the perinatal period and during childhood.

R K Russell, R Farhadi, M Wilson, H Drummond, J Satansji, D C Wilson Gastrointestinal Unit and Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

Correspondence to: Dr R K Russell, Gastrointestinal Unit, University of Edinburgh, Department of Medical Sciences, Edinburgh EH4 2XU, UK; richardrussell77@hotmail.com

Conflict of interest: None declared.

An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome

The surgical option for treatment of a patient with screen detected colorectal cancer (CRC) from a family with hereditary non-polyposis colorectal cancer (HNPCC) is subtotal colectomy or segmental resection. Using decision analysis, we showed that subtotal colectomy performed at a young age leads to an increased life expectancy (LE) of 1–2.3 years. Based on these results and the high risk of developing a second CRC, we concluded that if CRC is detected in a young patient participating in a surveillance programme, colectomy with ileorectal anastomosis seems to be the treatment of choice. A French Committee on HNPCC commented on our study. Firstly, they stated that using quality adjusted LE would be a more accurate approach for colorectal cancer. Secondly, they agreed that the patient’s choice is pivotal in decisions on prophylactic surgery, after being fully informed of the pros and cons of the surgical options.

H F A Vasen

The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, the Netherlands

W H de Vos tot Nederveen Cappel

Department of Gastroenterology, Leiden University Medical Centre, Leiden, the Netherlands

Correspondence to: Dr H F A Vasen, The Netherlands Foundation for the Detection of Hereditary Tumours, Rijnborssingel 10, 2333 AA, Leiden, the Netherlands; hfvasen@wxs.nl

doi: 10.1136/gut.2005.075820

Conflict of interest: None declared.
References


Defective denominators

I was interested in the paper by Langlands et al in which “prebiotic” carbohydrates altered the mucosal flora but apparently had no effect on cell proliferation (Gut 2004;53:1610–16). The matter is of some importance as the products of in vivo fermentation (short chain fatty acids) may increase epithelial cell proliferation, leading to the possibility that such supplements could actually enhance the risk of colorectal cancer.1,2

The authors state that methodology (of gut microscopy) is always an important issue and I argue that this also applies to cell proliferation studies, as the results of the present work may be misleading on two counts. Firstly, I would never recommend the use of Ki67 cell nuclear antigen as a marker of cell proliferation as: (1) the method is difficult to standardise; (2) the antigen has a long half life; and (3) anomalous expression has been demonstrated in non-cycling near tumours and after administration of growth factors.1,3 For sections, Ki67 is far better however even using this antibody the results of the present study are unlikely to be conclusive as only 2–4 crypts could be scored for; for most studies I would recommend scoring 30 hemi crypts.

The second point is that reliance on labelling indices can be misleading as lack of difference does not necessarily mean no proliferative change as both sides of the ratio (labelled cells divided by number of cells) could have altered. This was demonstrated in our studies of epidermal growth factor in parenterally fed rats where no differences in labelling index between orally fed and parenterally fed rats could be seen despite halving tissue weight and crypt cell production. When the data were re-expressed as labelling per crypt, the effects of treatment became apparent, a similar effect was seen in the stomach following misoprostol treatment.1

There is however a far easier and well validated method available for the study of human tissue. This is the so-called microdissection technique in which small pieces of stained material are teased apart and mitotic figures scored.3 This literally allows one to score over 100 crypts (if so wished) and as the results are expressed per crypt the effects of changes in denominator are automatically accounted for.4

R A Goodlad

Correspondence to: Dr R A Goodlad, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK; goodlad@cancer.org.uk

Conflict of interest: None declared.

References


Author’s reply

We thank Goodlad for his interest in our article. In our study (Gut 2004;53:1610–16), we assessed expression of cell proliferation using three markers that are most commonly used to indicate cell cycle entry in tissue sections. Importantly, there was no difference in the data obtained for all three. We agree that proliferating cell nuclear antigen is of limited value for the reasons mentioned by Goodlad and also the fact that the protein has a role in DNA repair, which reduces its specificity as a cell cycle marker. Similarly, Ki67 is not expressed by all cycling cells, may be downregulated by nutritional deprivation, and may also be involved in non-cell cycle related processes, such as ribosomal biosynthesis.1

We consider that the most useful markers of cycling cells are the minichromosome maintenance (MCM) proteins, which are abundant at all phases of the cell cycle and are downregulated following exit into quiescence, differentiation or senescence. MCMs therefore provide a sensitive and specific indication of cell cycle entry. In our opinion these markers are preferable to mitotic figures, which is a subjective and error prone exercise that by definition would appear to be more of an indicator of replication potential and, as such, are likely to be useful markers of dysplasia.2 In addition, scoring immunohistochemical labelled cells is just as, if not more, “subjective and error prone” than scoring mitotic figures (which are far easier to score in “squash” preparations than in sections). My main
Several groups have shown that many others have shown null effects and some of these, especially the intervention ones, demonstrated adverse effects. For example, wheat bran supplementation increased polyp recurrence in women and ispaghula had a more general adverse effect on polyps.1

Interpreting observational and intervention studies of fibre has filled many journal pages in recent years. There are numerous problems which, in the context of the present discussion, relate primarily to people treating all sources of fibre as being equal, thinking that fibre supplements will have the same effect as fibre present in whole foods in the diet and the amounts of fibre considered to be protective. With regard to the study by Alberts and colleagues, the fibre was provided as a supplement and was only of wheat bran. As Goodlad and Alferez correctly note, the EPIC study showed a protective effect for fibre when intrinsically part of the diet, and from mixed sources. In other words, it is a high fibre diet that protects. The Bonithon-Kopp study used a fibre supplement, ispaghula, not found in most diets in the field, and at a very small dose of only about 3 g/day.


doi: 10.1136/gut.2005.072447 on 14 September 2005. Downloaded from

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.

Conflict of interest: None declared.
Laterally spreading tumour in which interstitial deletion of β-catenin exon 3 was detected

Laterally spreading tumours (LSTs) of the colon and rectum are defined as lesions greater than 10 mm in diameter with a low vertical axis that extend laterally along the luminal wall. As most LSTs remain as adenomas or early invasive cancers, LSTs have been thought to have relatively little malignant potential. LSTs are divided into two macroscopic subtypes: flat (F)-type, which is composed of superficially spreading lesions with flat and smooth surfaces, and granular (G)-type, which is composed of superficially spreading aggregates of nodules. Despite distinctive biological behaviours of LSTs, only a few genetic alterations have been reported, such as K-ras and p53 mutations and cycllooxygenase 2 overexpression.

A 62 year old Japanese woman was referred to our hospital for treatment of a colonic tumour. Colonoscopy in our hospital showed an F-type LST with a central depression surrounded by a flat elevated area with a smooth surface in the caecum (fig 1A). Microscopically, the tumour consisted of a well differentiated adenocarcinoma with a tubular adenoma and had invaded the submucosal layer.

After obtaining informed consent from the patient, genetic analysis was carried out. No genetic alterations were found in APC, K-ras, or p53 genes. To clarify relevant alterations of gene expression, we analysed the gene expression profiles by a cDNA array.6 Among 350 cancer related genes, bone morphogenetic protein 4 (BMP4) was one of the most differentially expressed genes in tumour tissues and matched normal tissues (fig 1B). BMP4 is a member of the transforming growth factor (TGF)-β superfamily of growth factors. As BMP4 expression is reportedly correlated with oncogenic β-catenin in human colon cancer cells,7 we analysed alterations in β-catenin in tumour tissues. Intense nuclear expression of β-catenin was immunohistochemically seen within the nuclei of tumor cells (fig 1C). No point mutations of β-catenin were detected. Intersitial deletion was then examined by polymerase chain reaction. A shorter band was detected in both carcinoma and adenoma tissues compared with the normal size of 931 bp. CA, carcinoma tissue; TA, tubular adenoma tissue; N, normal tissue.

Figure 1 (A) Endoscopic picture with indigocarmine dye spraying showing an F-type laterally spreading tumour with a central depression surrounded by a flat elevated area in the caecum. (B) cDNA array hybridisation image of the tumour and non-tumour tissues. Bone morphogenic protein 4 (BMP4) was one of the most differentially expressed genes in the tumour tissues and matched normal tissues. (C) Intense nuclear expression of β-catenin immunohistochemically seen within the nuclei of tumour cells. (D) Intersitial deletion examined by polymerase chain reaction spanning the genomic region flanking exon 3 and the surrounding introns. A shorter band was detected in both carcinoma and adenoma tissues compared with the normal size of 931 bp. CA, carcinoma tissue; TA, tubular adenoma tissue; N, normal tissue.

Figure 2 DNA sequencing showing interstitial deletion of the 394 bp region in tumour tissue. Three base inverted repeats, AGC and GCT, were found in sequences flanking the interstitial deletion. The deletion included the part of exon 3 containing critical serine and threonine codons for GSK-3β phosphorylation.
present patient had no past history or family\nhistory of cancer. It would be interesting to\ninvestigate whether β-catenin mutation posi-\ntive HNPCC cancers have any specific mor-\nphological features.

K Nosho, H Yamamoto, M Mikami,\nT Takahashi, Y Adachi, T Endo\nFirst Department of Internal Medicine, Sapporo\nMedical University, Sapporo, Japan

K Hirata\nFirst Department of Surgery, Sapporo Medical\nUniversity, Sapporo, Japan

K Imaizumi, Y Shinomura\nFirst Department of Internal Medicine, Sapporo\nMedical University, Sapporo, Japan

Correspondence to: Dr K Nosho, First Department\nof Internal Medicine, Sapporo Medical University, S-1,\nW-16, Chuo-ku, Sapporo 060-8543, Japan;\nnosho@sm.ac.jp

doi: 10.1136/gut.2005.075184

Conflict of interest: None declared.

References

1 Kudo S. Endoscopic mucosal resection of flat and\ndepressed types of early colorectal cancer.\nEndoscopy 1993;25:455–61.

2 Tanaka S, Hashmi K, Oka S, et al.\nClinicopathologic features and endoscopic\ntreatment of superficially spreading colorectal\nnecrotizing tumours larger than 20 mm. \nGastrointest Endosc 2001;54:62–6.


Functional role of the 503F variant of the organic cation\ntransporter OCTN1 in Crohn’s\ndisease

Several susceptible gene loci were identified as\nbeing involved in the aetiology of Crohn’s\ndisease (CD). Recently, a non-synonymous single nucleotide polymorphism in the\nSLC22A4 gene encoding the organic cation\ntransporter OCTN1 has been linked with CD\nin Caucasian populations (a 1672CT transver-\nsion, resulting in the amino acid substitution\nL503F). However, the functional conse-\nquences of this alteration are unclear as yet.

We have now discovered that L-ergothio-\n neine (ET, 2-mercaptotetrahydrothiophene\ntrioxide), a naturally occurring water soluble\nthiol compound of dietary origin, is one of\nthe physiological substrates of OCTN1. Analysis\nof the concentration dependence of ET\ntransport in OCTN1 transfected HEK293 fibroblasts by liquid chromatography tandem \nmass spectrometry revealed that the 503F\nvariant was associated with a threefold\nhigher substrate affinity (1/Km) and a two-\nfold lower maximal transport velocity (V_{\text{max}}),\nwhich resulted in a 50% higher initial\ntransport capacity (V_{\text{max}}/K_{\text{m},503F}) \approx 1.5 \times\nV_{\text{max}}/K_{\text{m},503L}) at low ET levels (\(< 10 \mu\text{mol/l})\\n(fig 1A). Analysis of the time course of ET\ntransport showed a higher clearance for the\n503F variant (CL, 503F \approx 1.65 \times CL (503L)\n(fig 1B). ET transport by 503L and 503F was sodium

### Figure 1

Ergothioneine and OCTN1. Concentration dependence, K_{m}, and V_{max} of specific ergothioneine (ET) uptake in HEK293 cells constitutively expressing the 503L variant or the 503F variant after one minute of loading (A); specific uptake and clearance (CL) over a time course after incubation with 10 µmol/ET (B); effects of sodium (C) and pH (D) on specific uptake after one minute of loading with 10 µmol/ET. In sodium reduced transport buffer, NaCl was isotopically replaced with choline chloride (which did not interfere with ET transport). An equal expression level of both OCTN1 mRNA levels was controlled by quantitative real time polymerase chain reaction. (Fig 1A). Linear correlation of ET concentrations in CD14+ monocytes (fractionated from peripheral blood mononuclear cells) with OCTN1 mRNA expression (relative to the housekeeping gene GAPDH, lowest expression was set to 1) in eight healthy volunteers that were homozygous carriers of the 503L variant (E). MITT assay of the proliferation of Caco-2 colon tumour cells with and without OCTN1 mRNA expression after 24 hours of incubation with ET or glutathione. Resulting formazan formation was determined by absorbance at 568 nm (F). Data are means (SEM) of three (A–D) or 8–16 (F) independent experiments.\n
*\(p<0.05\), **\(p<0.01\), ***\(p<0.001\): significant differences between OCTN1 variants (A–D); significant differences compared with buffer controls (F), as determined by one way ANOVA with Holm-Sidak correction (\(x=0.05\)).
and pH dependent; only at unphysiologically low Na⁺ and pH values were the differences in transport activity between both variants lost (fig 1C). Considering that maximal levels of ET found in tissues and in common foods are in the nanomolar to low micromolar range, our data suggest that carriers of the 503F allele accumulate higher ET concentrations in OCTN1 expressing cells compared with carriers of the wild-type 503L allele. Therefore, high tissue levels of ET may constitute a possible risk factor for CD.

The involvement of OCTN1 in the inflammatory process is further supported by observations that OCTN1 is strongly expressed in intestinal epithelial and immunological cells, particularly in CD4+ monocytes/macrophages playing a key role in the immunopathogenesis of CD, as well as by the finding that levels of SLC22A4 mRNA were upregulated by proinflammatory cytokines such as tumour necrosis factor α. Moreover, we found transcriptional regulation of SLC22A4 in CD4+ monocytes/homoygous for the 503L variant, expression levels of SLC22A4 mRNA showed high interindividual heterogeneity and were directly proportional to cellular ET content (fig 1E). Accordingly, in CD4+ and CD8+ lymphocytes lacking OCTN1 expression, we detected no ET (data not shown).

The physiological or pathophysiological functions of ET are as yet unknown. We tested the effect of ET on proliferation of the colon cancer epithelial cell line Caco-2 that was shown to be homozygous for the 503F allele and to express high levels of OCTN1 mRNA. Cell proliferation was enhanced in a dose dependent manner after exposure to ET concentrations above 20 μmol/l for 24 hours: at 200 μmol/l, proliferation was increased to 120 (3%) of the buffer control and intracellular ET concentration reached 6.7 (0.3) nmol/mg protein. In contrast, no stimulation of proliferation was seen when a Caco-2 variant without OCTN1 lost (fig 1C, D). Considering that maximal ET concentrations in OCTN1 expressing cells could be reached 6.7 (0.3) nmol/mg protein occurred. When incubated with glutathione, both Caco-2 cell lines exhibited an antioxidant typical inhibition of proliferation that was independent of OCTN1 expression (fig 1F). ET, rather than antioxidant activities, stimulatory effects on cell proliferation appear to constitute the functional role of ET. ET may accelerate the inflammatory process by transcriptional activation of proinflammatory cytokines such as tumour necrosis factor α. Furthermore, ET may act as a modulatory factor for expression levels of SLC22A4 mRNA that was independent of OCTN1 expression levels. Therefore, high tissue levels of ET may accelerate the inflammatory process by transcriptional activation of proinflammatory cytokines such as tumour necrosis factor α. Furthermore, ET may act as a modulatory factor for expression levels of SLC22A4 mRNA that was independent of OCTN1 expression levels. Therefore, high tissue levels of ET may constitute a possible risk factor for CD.

Collectively, our data suggest that the OCTN1 substrate ET is a proliferative factor in inflamed tissues such as CD, and subjects carrying the 503F allele are at an increased risk due to a higher intracellular accumulation of ET.

Correspondence to: Dr D Taubert, Department of Pharmacology, Medical Hospital of the University of Cologne, Germany. E-mail: dirk.taubert@medizin.uni-koeln.de

doi: 10.1136/gut.2005.076083

* D Taubert and G Grimbarg contributed equally to this study.

Conflict of interest: None declared.

High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease

Disease related prion protein (PrPSc) is readily detectable in lymphoreticular tissues in variant Creutzfeldt-Jakob disease (vCJD) but not in other forms of human prion disease. This distinctive pathogenesis together with the unknown population prevalence of asymptomatic vCJD infection has led to significant challenges in understanding the epidemiology and clinical presentation of vCJD.
Concerns that secondary transmission of vCJD prions will occur through a wide range of surgical procedures. Risk assessment for intestinal endoscopy, biopsy, and surgery is currently limited by a lack of knowledge about relative PrPSC levels and prion titres within intestinal tissues in vCJD patients. Because of its high content of lymphoid follicles, terminal ileum is regarded as the intestinal tissue having the highest potential for iatrogenic transmission of vCJD prions. Here we provide the first report of relative PrPSC concentrations in vCJD terminal ileum.

Tissues were obtained at autopsy with consent from relatives of four patients with neuropathologically confirmed vCJD and two patients with neuropathologically confirmed sporadic CJD (both PRNP codon 129MM with type 2 PrPSC in brain). Terminal ileum was analysed for PrPSC by high sensitivity immunoblotting and for abnormal PrP immunoreactivity by immunohistochemistry. Using these methods, terminal ileum from all four vCJD cases showed high levels of detectable PrPSC (fig 1A). In three vCJD cases, 2/2 homogenates prepared from each ileum specimen were positive for PrPSc whereas 2/4 ileum homogenates were positive in the other vCJD case. The glycosylation ratio of protease resistant fragments of di-, mono-, and non-glycosylated PrP in terminal ileum appeared to be closely similar to the type 4 PrPSc pattern seen in vCJD tonsil.

Although there was variation in PrPSc concentration between different homogenates of vCJD terminal ileum, PrPSc levels in positive samples were typically in the range 0.1-1% of that present in vCJD brain (fig 1B). With respect to both sampling variation and PrPSc concentration, terminal ileum appears to be closely similar to lymph nodes in vCJD. These findings, together with our previous studies, show that PrPSc deposition within the intestine is not uniform in vCJD. From the four cases of vCJD with PrPSc positive terminal ileum studied here, 0/2 cases with available tissue had detectable PrPSc in the appendix and only 1/3 cases had detectable PrPSc in the rectum. In contrast with findings with vCJD terminal ileum, no detectable PrPSc was found in homogenates of terminal ileum prepared from sporadic CJD patients (fig 1A). The lack of detection of PrPSc in sporadic CJD terminal ileum extends our previous findings for one of these cases in which we have previously reported a lack of detectable PrPSc in tonsil, rectum, and appendix.

In agreement with findings from immunoblotting, immunohistochemistry showed abnormal PrP deposition in the terminal ileum in vCJD (fig 1C) but not in sporadic CJD (data not shown). The irregular distribution of abnormal PrP positive lymphoid follicles seen in vCJD terminal ileum is consistent with variation in PrPSc concentration detected in different terminal ileum samples by immunoblotting.

Albeit from necessarily limited numbers investigated, the uniform presence of PrPSc in vCJD terminal ileum, at concentrations of up to 1% of those found in vCJD brain, reinforces concerns that iatrogenic transmission of vCJD prions might occur through contaminated intestinal endoscopes, biopsy forceps, or surgical instruments. These findings should assist policy makers in the UK and elsewhere in risk assessments about the use of disposable forceps for intestinal biopsy. Alternative approaches to risk reduction may now be possible as practical means of prion decontamination for endoscopes and surgical instruments are now feasible using enzymatic methods.

Acknowledgements
This study was funded by the UK Medical Research Council and was performed under the approval of the Institute of Neurology/National Hospital for Neurology and Neurosurgery Local Research Ethics Committee.

S Joiner, J M Linehan, S Brandner, J D F Wadsworth, J Collinge
MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, London, UK

Correspondence to: Professor J Collinge, MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; j.collinge@prion.ucl.ac.uk

Conflict of interest: declared (the declaration can be viewed on the Gut website at http://www.gutjnl.com/supplemental)

Figure 1 (A, B) High sensitivity immunoblots using anti-prion protein (PrP) monoclonal antibody 3F4. (A) Proteinase K digested sodium phosphotungstic acid pellets from 0.5 ml of 10% terminal ileum homogenates from variant Creutzfeldt-Jakob disease (vCJD) patients 1–4 or sporadic CJD (sCJD) patients 1 and 2. (B) Proteinase K digested sodium phosphotungstic acid pellets from 0.5 ml of 10% normal human tonsil homogenate (normal tonsil) or 0.5 ml of 10% normal human tonsil homogenate spiked with 2.5 μl of 10% brain homogenate from vCJD patient No 4 (spiked tonsil) were compared with a proteinase K digested sodium phosphotungstic acid pellet from 0.5 ml of 10% terminal ileum homogenate from the same vCJD patient. (C) Photomicrograph showing abnormal PrP immunoreactivity in a lymphoid follicle in vCJD terminal ileum (anti-PrP monoclonal antibody 1C5). Scale bar, 100 μm. Inset, high power magnification of PrP deposits.

References
3 Wadsworth JBF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive
Chronic inflammatory intestinal diseases and bone loss

We were very interested in the recent article by Moschen et al on activation of the RANKL/OPG system in inflammatory bowel disease (IBD) (Gut 2005;54:479–87). Until recently, osteoporosis secondary to gastrointestinal diseases was mainly considered a direct consequence of malabsorption. 1 The article of Moschen et al and a previous one of our group on bone loss in coeliac disease, 2 a disorder similarly characterised by intestinal inflammation, offer a new perspective on the pathogenesis of bone loss and reveal a more complex picture. Moschen et al demonstrated overproduction of OPG in the cells of colonic mucosa in IBD whereas Tarantina and colleagues 3 showed the direct role of the soluble cytokines in the serum of coeliac patients on bone cells. In fact, they found an increased RANKL/OPG ratio in untreated coeliac patients and different effects of the sera of untreated coeliac patients with respect to those on a gluten free diet, on cultured bone cells. These effects included increased in vitro osteoclastogenesis, and lower interleukin 18 and OPG expression in osteoblasts.

In both studies, these biochemical observations were translated in a reduction of bone mass. Moschen et al found a negative correlation between OPG plasma levels and spine and femoral bone mineral density (BMD). Tarantina and colleagues 1 observed a significant negative correlation between BMD z score and interleukin 6 levels and RANKL/OPG ratio. In the discussion, Moschen et al observed that “studies of OPG/RANKL and BMD are required to validate” his model.

We believe that our study may be a first step towards understand, at least in part, the role of inflammation of bone loss in intestinal diseases. These results are also in accordance with recent studies on primary osteoporosis, which are beginning to show a relevant role of local and systemic factors on bone cell activity. 4 Finally, these studies may also open the way to different therapeutic approaches—namely, drugs specifically acting on cytokines release and/or activity—for bone loss secondary to “inflammatory intestinal diseases”.

M T Bardella
Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, IRCCS, Milano, Italy

M L Bianchi
Bone Metabolism Unit, Istituto Auxologico Italiano, IRCCS, Milano, Italy

A Teti
Department of Experimental Medicine, University of L’Aquila, L’Aquila, Italy

Correspondence to: Dr M T Bardella, University of Milano, Mangiagalli e Regina Elena, IRCCS, Via Francesco Sforza, 33 Milano, Italy; manateresa.bardella@unicam.it

Conflict of interest: None declared.

References

Gut: first published as 10.1136/gut.2004.045203corr1 on 14 September 2005. Downloaded from http://gut.bmj.com/ on May 29, 2022 by guest. Protected by copyright.